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Introduction
Isoflavones are biologically active compounds that are
naturally present in foods of plant origin. They have
received considerable attention because of their potential
cancer preventive, cardioprotective and bone sparing
effects, and because of their potential to provide relief
from menopausal symptoms [1,2]. Soybeans are particularly
rich sources of isoflavones such as daidzein and genistein
BMI = body mass index; ESR1 = estrogen receptor; FSH = follicle-stimulating hormone; HPLC = high-pressure liquid chromatography; HRT =
hormone replacement therapy; LH = luteinizing hormone; PABA = para-amino benzoic acid; SD = standard deviation.
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Abstract
Introduction: Isoflavones are hypothesized to protect against
breast cancer, but it is not clear whether they act as oestrogens
or anti-oestrogens in breast tissue. Our aim was to determine
the effects of taking a red clover-derived isoflavone supplement
daily for 1 year on mammographic breast density. Effects on
oestradiol, follicle-stimulating hormone (FSH), luteinizing hormone
(LH), lymphocyte tyrosine kinase activity and menopausal
symptoms were also assessed.
Methods: A total of 205 women (age range 49–65 years) with
Wolfe P2 or DY mammographic breast patterns were randomly
assigned to receive either a red clover-derived isoflavone tablet
(26 mg biochanin A, 16 mg formononetin, 1 mg genistein and
0.5 mg daidzein) or placebo. Change in mammographic breast
density, serum oestradiol, FSH, LH, menopausal symptoms and
lymphocyte tyrosine kinase activity from baseline to 12 months
were assessed.
Results: A total of 177 women completed the trial. Mammo-
graphic breast density decreased in both groups but the
difference between the treatment and placebo was not
statistically significant. There was a significant interaction
between treatment group and oestrogen receptor (ESR1) PvuII
polymorphism for the change in estimated percentage breast
density (mean ± standard deviation): TT isoflavone 1.4 ± 12.3%
and TT placebo –9.6 ± 14.2%; CT isoflavone –5.2 ± 12.0%
and CT placebo –2.8 ± 10.3%; and CC isoflavone
–3.4 ± 9.7% and CC placebo –1.1 ± 9.5%. There were no
statistically significant treatment effects on oestradiol, FSH, or
LH (assessed only in postmenopausal women), or on
lymphocyte tyrosine kinase activity. Baseline levels of
menopausal symptoms were low, and there were no
statistically significant treatment effects on frequency of hot
flushes or other menopausal symptoms.
Conclusion: In contrast to studies showing that conventional
hormone replacement therapies increase mammographic
breast density, the isoflavone supplement did not increase
mammographic breast density in this population of women.
Furthermore, there were no effects on oestradiol,
gonadotrophins, lymphocyte tyrosine kinase activity, or
menopausal symptoms.
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[3], and intakes of isoflavones are markedly higher among
Asian populations than in Western ones, largely resulting
from soy consumption patterns [4,5]. It is widely perceived
that exposure to isoflavones is beneficial because rates of
breast cancer and other hormone-dependent conditions
are lower in Asian than in Western countries [6–8].
However, isoflavones can act as weak oestrogens, and
two intervention studies with soy have provided evidence
for stimulatory effects of isoflavones on breast tissue [9,10].
Mammographic breast density, characterized by the
relative proportions of radiolucent fat and radiodense
connective and epithelial tissue within the breast, has
consistently been associated with risk for breast cancer. In
a review of case–control studies [11], odds ratios for
breast cancer among women with the highest versus the
lowest extents of density ranged from 2.1 to 6.0. The
mechanism underlying this relationship has not been fully
explained, but it has been suggested that breast density
provides an index of current and past hormonal and
reproductive events that modulate risk for breast cancer
[12]. In support of this, studies have shown that breast
density increases when a woman begins hormone
replacement therapy (HRT) and decreases when she
discontinues [13–18], and anti-oestrogens such as
tamoxifen reduce breast density [19–21]. As a result of
such findings, we suggested that breast density can act
as a biomarker of oestrogenic or anti-oestrogenic effects
of a given treatment on breast tissue [22].
Diet has been shown to influence breast density,
potentially through effects on endogenous hormone levels.
For example, a low-fat, high-carbohydrate intervention
significantly reduced breast density [23]; however, an
inverse association has also been reported between
breast density and saturated fat intake [24]. In a cross-
sectional study of diet and mammographic density, total
protein and carbohydrate intake was significantly and
positively associated with breast density, and among
postmenopausal women there was a significant positive
association between total meat intake and breast density
[25]. More recently, data from a cross-sectional study of
soy food intakes and mammographic densities [26]
indicated the presence of a significant trend toward higher
percentage density through increasing quartiles of soy
intake, but a small study of a soy isoflavone supplement
[27] did not significantly alter breast density after 1 year of
treatment.
Here, we report the results of a randomized, placebo-
controlled trial that was conducted to determine the
effects of a red clover-derived isoflavone supplement,
taken daily for 1 year, on mammographic breast density. In
addition, effects on circulating levels of oestradiol,
gonadotrophins, lymphocyte tyrosine kinase activity, and
menopausal symptoms are reported, and interactions
between treatment group and polymorphisms in CYP17,
CYP19, and oestrogen receptor (ESR1) genes.
Methods
Recruitment
Women were recruited from the Breast Screening Unit,
Addenbrooke’s Hospital, Cambridge, UK. Between
November 1997 and May 1999, mammograms from 1908
healthy women aged 49–65 years were classified accord-
ing to Wolfe pattern [28] and recruitment letters were sent
to women with Wolfe P2 or DY breast patterns (n = 1149;
Fig. 1). The letter contained a short description of the
study and a reply slip. Women with a history of breast
cancer and/or major breast surgery were not approached.
Women who expressed an interest in taking part, and who
were not taking HRT, were visited in their own home.
During this initial home visit the study was explained in
detail, and all women who wished to participate were
asked for written informed consent. A total of 205 women
were randomized (Fig. 1). Additional home visits were
made after approximately 5.5 and 11 months on the study.
All study procedures were approved by the Dunn Human
Nutrition Unit Ethics Committee, and the Cambridge Local
Research Ethics Committee.
Intervention and randomization
Participants were randomly assigned to receive either an
isoflavone tablet providing 26 mg biochanin A, 16 mg
formononetin, 1 mg genistein and 0.5 mg daidzein derived
from red clover (Promensil; Novogen Ltd, Sydney,
Australia) or a placebo of identical appearance. Participants
were asked to take one tablet each day for 1 year. An
independent study has shown that Promensil tablets
contain the quantity and type of isoflavones stated by the
manufacturer [29]. Randomization was performed by the
Outpatient Pharmacy, Addenbrooke’s Hospital, Cambridge,
UK, using random number generation in Microsoft Excel.
Researchers and study participants remained blinded to
tablet allocation throughout the study.
Mammographic density
Recruitment mammograms that were taken as part of the
National Health Service Breast Screening Programme
were used as the baseline measure, and women were
scheduled to undergo a follow-up mammogram after
approximately 12 months on the study. Independently of
each other, and blinded to intervention or placebo status,
two radiologists (RMLW and ES) assigned Wolfe patterns
[28] and visually estimated the percentage density on
each set (left and right mediolateral oblique views) of
mammograms. Estimated percentage densities were
assigned by drawing a cross on a 100 mm line
(representing 0–100% density), and the distance from the
start of the line and the cross was measured.
Mammograms from the left and right breasts were
presented to the radiologists, and an average of bothBreast Cancer Research    Vol 6 No 3 Atkinson et al.
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breasts was used for assigning Wolfe pattern and
estimated percentage density. One radiologist (RMLW)
read baseline mammograms at the time of recruitment,
and follow up mammograms at the end of the study, and
another (ES) read all mammograms at the end of the study
but was unaware of the sequence in which the
mammograms had been taken (i.e. baseline or follow up).
Correlations between estimated percentage densities
assigned by both radiologists were highly significant for
the baseline and 12-month mammograms (r = 0.79,
P < 0.01 and r = 0.85,  P < 0.01, respectively). Excellent
(99%) observer agreement between the two radiologists
has previously been reported for the P2 and DY
categories [30]. In all statistical analyses, the average of
the two radiologists’ independent readings of percentage
breast density was used. Two women in the placebo
group had mammograms taken before the end of the
study (because of suspicious palpable lumps), and one
woman (also in the placebo group) did not attend her
follow-up appointment.
Menopausal symptoms
All women were asked to complete a 28-day menopausal
symptom diary at baseline and after approximately
12 months on the study [31]. They were asked to rate the
severity of 21 symptoms associated with the menopause,
including night sweats, heart beating quickly or strongly,
feeling tense or nervous, difficulty in sleeping, irritability,
and feeling unhappy or depressed. Severity ratings were
as follows: 0 = absent, 1 = mild, 2 = moderate and 3 =
severe. Women were also asked to note the number of
hot flushes experienced on each of the 28 days. For each
woman, a menopausal symptom score was calculated for
the baseline and 12 month diaries (severity ratings for
each symptom were averaged over the 28 days and a sum
of the mean severity ratings was taken).
24-Hour urine samples
Participants were asked to provide 24-hour urine
collections at baseline and after 12 months on the study.
As a compliance check, women also were asked to make
Figure 1
Flow chart describing progress of participants through trial. *Includes two women who completed the trial but were excluded from all analyses
because they had taken an oral contraceptive (OC) or were being treated for alcoholism. **Includes one woman who was excluded from all
analyses because she had taken an OC, two women who had mammograms taken before the end of the study, and one woman who did not attend
her follow-up mammogram. HRT, hormone replacement therapy.a 24-hour urine collection after 6 months. Collection
bottles (containing 2 g boric acid/l as a preservative) and
three para-amino benzoic acid (PABA) tablets (80 mg/tablet)
were given to each participant at each of the three home
visits [32]. Verbal and written instructions were given, and
for each collection participants were asked to discard the
first urine specimen of the day and to collect all
subsequent samples up to and including the first specimen
passed the following morning. Participants were asked to
take one PABA tablet with each main meal on the day the
collection began, and this was used to determine the
completeness of urine collection (see below). Samples
were brought to the laboratory in the morning on which the
urine collection had been completed. Once received at the
laboratory, samples were mixed thoroughly and the total
volume of urine was measured. Three 25 ml aliquots were
taken and stored at –20°C.
Urinary para-amino benzoic acid and isoflavone analysis
The PABA content of all 24-hour urine samples was
measured using previously described methodology [32].
Samples containing 85–110% of the ingested PABA
were designated satisfactory. For samples with PABA
recoveries of between 70% and 85% (indicating that all
tablets had been taken but that the urine collection was
incomplete), urinary excretion of isoflavones was adjusted
up to 93% PABA recovery [33]. Samples with less than
70% recovery were designated incomplete. Samples with
greater than 110% PABA recovery were designated
unsatisfactory, because additional sources of PABA may
have been consumed (e.g. a multivitamin) and an accurate
determination of sample completeness could therefore not
be made.
Urinary excretions of genistein, daidzein, formononetin and
biochanin A were measured by high-pressure liquid
chromatography (HPLC) using a method modified from
that of Setchell and coworkers [34] and Franke and
coworkers [35]. Briefly, samples were incubated with
β-glucuronidase for 20–72 hours at 37°C. Phenolic
components were extracted into an ethyl-acetate (6:4)
solvent mixture. Following 0.5-min vortex and subsequent
10-min centrifugation, the organic phase was transferred
to a 2-ml vial and evaporated to dryness under vacuum at
43°C. Extraction residues were reconstituted in 100 µl
50% isopropanol solution and centrifuged for 10 min. A 5 µl
aliquot was then injected directly onto the HPLC column;
the HPLC column consisted of an Alltima 250 × 2.1 mm,
5 µmol/l, C-18 stationary phase (Alltech Associates,
Sydney, New South Wales, Australia), and a mobile phase
(acetonitrile/water) containing 0.05% trifluoroacetic acid
with a gradient of acetonitrile from 25% to 100% was
used for each run. Detection and quantification were via
photo diode array detector. Flavone was used as the
internal standard, and the limit of detection was 0.05 µg/ml
and the limit of quantitation was 0.1 µg/ml. Baseline or
12-month urine samples were unavailable for two women in
the isoflavone group and three women in the placebo group.
Blood samples and body mass index
Fasting blood samples were taken at baseline and at
12 months. Participants were asked to refrain from eating
or drinking beverages (except water) from midnight until
after the sample had been taken the following morning. A
total of 35.5 ml blood was drawn at each visit, which
included 9.0 ml blood that was drawn into a lithium
heparin tube, 9.0 ml into a serum tube, 9 ml into an EDTA
tube and 4 ml into an additional EDTA tube. The serum
tube was left at room temperature for at least an hour
before centrifugation to allow clotting. Following centrifu-
gation, aliquots of plasma and serum were stored at
–20°C. Lymphocytes were extracted from the EDTA tubes
(total 13 ml whole blood) using Lymphoprep tubes
(Nycomed Pharma AS, Oslo, Norway) and stored at
–20°C. Approximately 1 ml whole blood was removed
from the lithium heparin tube before centrifugation, and
DNA was extracted using a QIAGEN kit (QIAGEN Ltd,
Crawley, UK). Polymorphisms in the CYP17 gene (5′
untranslated MspA1 polymorphism) and the CYP19 gene
(G → T substitution on intron 6) were determined as
described previously [36,37]. The PvuII polymorphism
(generated by a C → T substitution on intron 1) in the
ESR1 gene was determined via an automated method
using TaqMan™ (Applied Biosystems, Cheshire, UK) [38].
The primers used were ESR1-F (TGTTGTCCATCAGTT-
CATCTGAGT) and ESR1-R (AACTCTAGACCACAC-
TCAGGGTCTCT) and the probes were (AATGTCCCA-
GCCGTTTTATGCTTTGT) labelled with TET and (AAA-
TGTCCCAGCTGTTTTATGCTTTGTCT) labelled with FAM
(Applied Biosystems). Reactions were conducted
according to manufacturer’s instructions and detected
using an ABI Prism 7700 Sequence Detector (Applied
Biosystems).
Participants’ height and weight were measured at baseline
and 12 months, and body mass index (BMI) was
calculated as follows: weight (kg)/height (m2).
Oestradiol and gonadotrophins, and menopausal status
Serum oestradiol was measured using previously described
methodology [39]. Luteinizing hormone (LH) and follicle-
stimulating hormone (FSH) were measured using enzyme
immunoassay on an Abbott Axsym automated analyzer
(Abbott Diagnostics, Maidenhead, UK). Baseline and
12-month samples for each participant were assayed in
the same batch. The limit of detection for oestradiol was
3.0 pmol/l. Menopausal status was determined using
baseline levels of oestradiol and FSH as follows: women
were classed as premenopausal if FSH <30 IU/l and
oestradiol >100 pmol/l; postmenopausal if FSH >30 IU/l
and oestradiol <100 pmol/l; and perimenopausal if FSH
>30 IU/l and oestradiol >100 pmol/l, or if FSH <30 IU/l
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noted on her questionnaire at the initial home visit that she
was currently menstruating, but her baseline hormone
profile was that of a postmenopausal woman (i.e. FSH
>30 IU/l and oestradiol <100 pmol/l), then she was
classed as perimenopausal.
Tyrosine kinase
Lymphocytes were lysed according to methods reported
elsewhere [40] and analyzed for tyrosine kinase activity
using an enzyme-linked immunosorbent assay based kit
and corrected for protein content (Tyrosine Kinase Assay
Kit [product no. 29904] and BCA Protein Assay kit
[product no. 23225]; Pierce, Rockford, IL, USA).
Data analysis
Based on the findings of our previous study on the effects
of tamoxifen on breast density [19], we estimated that
20% of women in the isoflavone group and 5% of the
women in the placebo group would change to a more
lucent Wolfe pattern. Thus, to yield 80% power to detect
a difference between treatment groups at the 5%
significance level (two-tailed), a sample size of 76 women
per treatment arm would be needed [41]. Statistical
analyses were performed using the SAS statistical
package version 6.12 (SAS Institute, Cary, NC, USA).
Pearson correlation coefficients and Student’s t-tests
were used to assess inter-reader agreement in estimated
percentage breast density. Changes in estimated
percentage breast density, oestradiol, FSH, LH, tyrosine
kinase activity, menopausal symptom score, and number
of hot flushes from baseline to 12 months were expressed
as absolute change (i.e. 12-month data – baseline data).
Differences between treatment groups for changes in
breast density and tyrosine kinase activity were tested
using an unpaired t-test. Data for changes in oestradiol,
FSH, LH, hot flushes, and menopausal symptom score
were skewed, and therefore the nonparametric Wilcoxon
rank sum test was used to test for differences between
treatment groups. Changes in oestradiol, FSH, and LH
were assessed only in postmenopausal women because
of absence of data on phase of menstrual cycle in which
blood samples were taken. A general linear model (using
the SAS command PROC GLM) was used to determine
interaction in effects of genotype on baseline measures
and on change from baseline to 12 months. Three women
who completed the study were excluded from all analyses
either because they had taken an oral contraceptive
regularly during the study (one in the isoflavone group, and
one in the placebo group) or because they were being
treated for alcoholism (one in the isoflavone group).
Results
Withdrawals and baseline data
Twenty-eight women withdrew from the study (Fig. 1);
principal reasons for withdrawal were commencement of
HRT and work commitments/family problems preventing
completion of study activities. Other reasons included
feeling no beneficial effects of the intervention or no
interest in continuing on the trial, heavy menstrual bleeding,
and illnesses preventing completion of study activities
(e.g. severe hip pain, skin irritation and sores, sickness
and diarrhoea). One woman in the isoflavone group was
diagnosed with an interval cancer of the breast (i.e. a
cancer detected in the interval after a negative mammo-
graphic result) 2 months after the start of the intervention
and was withdrawn from the study. The difference
between treatment groups in the number of withdrawals
was not statistically significant (χ2 = 1.123, P = 0.29).
Age (mean ± standard deviation [SD]) was 55.1 ± 4.7
years for women in the isoflavone group and 55.2 ± 4.9
years for those in the placebo group (P = 0.65), and BMI
(mean ± SD) was 25.3 ± 3.9 kg/m2 and 25.3 ± 3.5 kg/m2
for women in the isoflavone and placebo groups,
respectively (P = 0.90). Percentages of women who were
premenopausal, perimenopausal and postmenopausal
were 16%, 14% and 67%, respectively, for women in the
isoflavone group, and 17%, 16% and 68%, respectively,
for women in the placebo group (χ2 = 0.04,  P = 0.98).
Time intervals (mean ± SD) between the screening mammo-
gram and the start of the intervention, and between
baseline and 12-month mammograms were 92 ± 32 and
452 ± 45 days, respectively, for women in the isoflavone
group, and 87 ± 27 and 454 ± 43 days, respectively, for
women in the placebo group. Differences between treat-
ment groups were nonsignificant (P > 0.05). There were
no significant effects of genotype (for genotype
frequencies, see Table 1) on baseline breast density,
oestradiol, FSH or LH (P > 0.05).
Compliance
According to the PABA check method, 58%, 72% and
77% of the women had complete urine collections at
baseline, 6 and 12 months, respectively. A further 22%,
11% and 13% had PABA recoveries between 70% and
85% at baseline, 6 and 12 months, respectively. Differences
between treatment groups in summed isoflavone excretion
(sum of daidzein, genistein, formononetin and biochanin A)
were nonsignificant at baseline, but differences were
highly significant at 6 and 12 months (Fig. 2; data shown
do not include women with <70% or >110% PABA
recovery; inclusion of these women did not alter the
results). Among women in the placebo group, isoflavone
excretion did not change significantly from baseline to
6 months (P = 0.80) or from baseline to 12 months
(P = 0.15; Fig. 2).
Breast density
There were no differences between readers (RMLW and
ES) in estimated percentage density at baseline or follow-
up. Densities (mean ± SD) at baseline were 61.8 ± 14.4%
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(P = 0.86), and at follow-up they were 58.0 ± 16.5% and
57.4 ± 21.6% for RMLW and ES, respectively (P = 0.81).
According to RMLW, among women in the isoflavone and
placebo groups, respectively, 22% and 18% of women
changed to a more lucent Wolfe pattern, 78% and 80%
did not change, and 0% and 2% changed to a more
dense Wolfe pattern. Differences between treatment
groups were not statistically significant (χ2 = 3.57;
P = 0.31). According to ES, among women in the
isoflavone and placebo groups, respectively, 15% and
19% of women changed to a more lucent Wolfe pattern,
84% and 80% did not change, and 1% and 1% changed
to a more dense Wolfe pattern. Again, differences
between treatment groups were not statistically significant
(χ2 = 0.43; P = 0.81).
Interactions between treatment group and menopausal
status for changes in estimated percentage breast density
were nonsignificant (P > 0.05), and so changes were
assessed for the combined group. Percentage breast
density (mean ± SD) decreased in both treatment groups
to a similar extent: –3.2 ± 11.7% and –3.9 ± 11.7% among
women in the isoflavone and placebo groups, respectively
(P = 0.73; Fig. 3). When analyses were restricted to
women with complete urine collections (i.e. samples
containing 85–110% of ingested PABA) at all three time
points, or when analyses were adjusted for baseline age
and change in BMI, differences between treatment groups
remained nonsignificant (P=0.20 and P=0.88, respectively).
The interaction between treatment group and the ESR1
polymorphism was significant (P = 0.009). Changes in
estimated percentage breast density (mean ± SD) by
treatment group and ESR1 genotype were as follows: TT
isoflavone 1.4 ± 12.3% and TT placebo –9.6 ± 14.2%;
CT isoflavone –5.2 ± 12.0% and CT placebo –2.8 ± 10.3%;
and CC isoflavone –3.4 ± 9.7% and CC placebo
–1.1 ± 9.5%. There were no interactions between
treatment group and CYP17 or CYP19 genotypes.
Oestradiol, follicle-stimulating hormone, luteinizing
hormone and tyrosine kinase activity
There were no significant effects of treatment group on
change in oestradiol, FSH, or LH (Table 2). Restricting the
analysis to women with complete urine collections at all
three time points did not alter these results (data not
shown). The interaction between CYP19 gene poly-
morphism and treatment group was of borderline statistical
significance for the change in FSH (P = 0.05). Changes in
FSH (IU/l) by treatment group and CYP19 genotype were
as follows (mean ± SD): GG isoflavone 1.07 ± 12.74 and
GG placebo –5.80 ± 18.46; GT isoflavone –2.93 ± 9.35
and GT placebo –2.69 ± 10.98; and TT isoflavone
–10.63 ± 11.30 and TT placebo 1.00 ± 9.13.
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Table 1
Genotype frequencies by treatment group
Group
Gene/polymorphism Isoflavone Placebo P
CYP17a
TT 32 (40%) 33 (39%)
TC 36 (44%) 40 (47%) 0.92
CC 13 (16%) 12 (14%)
CYP19b
GG 21 (27%) 28 (32%)
GT 40 (51%) 45 (52%) 0.49
TT 18 (23%) 14 (16%)
ESR1c
CC 17 (22%) 19 (22%)
CT 39 (51%) 46 (53%) 0.95
TT 21 (27%) 22 (25%)
aCYP17 data not available for three and five women in the isoflavone
and placebo groups, respectively. bCYP19 data not available for five
and three women in the isoflavone and placebo groups, respectively.
cESR1 data not available for seven and three women in the isoflavone
and placebo groups, respectively. Percentages do not always add up
to 100% because of rounding.
Figure 2
Urinary isoflavone (sum of daidzein, genistein, formononetin and
biochanin A) excretion at baseline, midway, and at the end of the study,
excluding samples with <70% or >110% para-amino benzoic acid
recovery. Error bars represent ± standard error of the mean. Numbers
at each evaluation were as follows: baseline, 66 and 72 in the
isoflavone and placebo groups, respectively; 6 months, 70 and 73; and
12 months, 76 and 79. The difference in isoflavone excretion between
treatment groups was not statistically significant at baseline (P = 0.23),
but differences between treatment groups at 6 and 12 months were
highly significant (P < 0.001 and P < 0.001).For tyrosine kinase activity, data were available for 46
women in the isoflavone group and for 47 women in the
placebo group. There was no significant difference in the
mean change, from baseline to 12 months, in tyrosine
kinase activity (activity/µg protein) between isoflavone and
placebo groups (mean ± SD): 1.62 ± 2.18 for women in
the isoflavone group and 0.90 ± SD 2.72 for women in the
placebo group (P = 0.16).
Hot flushes and menopausal symptoms
Interactions between treatment group and menopausal
status for changes in menopausal symptom score and
number of hot flushes were not statistically significant
(P > 0.05). Among women who experienced hot flushes at
either assessment period, or among women whose
menopausal symptom score was greater than zero at
either assessment period, there were no significant effects
of treatment group on hot flushes or menopausal
symptoms (Table 3).
Discussion
Combined HRT is associated with an increased risk for
breast cancer [42,43] and an increase in mammographic
breast density [13,16,44]. Soy and phyto-oestrogens have
been proposed as potential natural alternatives to HRT
[45,46], but there are only limited data from small studies
on the effect of isoflavones on breast density. In the
largest and longest study conducted thus far, we did not
observe a significant effect of the clover-derived isoflavone
supplement, taken daily for 1 year, on mammographic
breast density. This is in agreement with a small, exploratory
study conducted in 30 premenopausal women [27], in
which there were no significant effects of a soy isoflavone
supplement, providing 100 mg/day isoflavones for
12 months, on mammographic breast density. In that
study, there was a slight increase in percentage density
among women taking the isoflavone supplement, but
differences between the intervention and placebo groups
were not statistically significant. In the present study,
breast density decreased to a similar extent in both
treatment groups. This was presumably due to natural
changes over time because an inverse relationship
between breast density and age exists (for review [11]).
The decrease in percentage density was of a similar
magnitude to that seen among control individuals in other
studies [20,47] but was not as great as the decreases
seen with anti-oestrogens such as tamoxifen [20].
An attractive hypothesis for the potential chemopreventive
actions of isoflavones is via modulation of endocrine
function. However, the literature is conflicting with regard
to the effects of soy intakes on circulating levels of
oestradiol in both premenopausal and postmenopausal
women; some studies have reported decreases,
increases, or little effect [9,48–53]. In a recent study of
premenopausal women [54], consumption of soymilk from
which the isoflavones had been removed resulted in a
decrease in oestradiol, suggesting that soy protein rather
than soy isoflavones may be responsible for the reduction
in circulating levels of oestradiol seen in some studies.
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Figure 3
Estimated percentage density (and 95% confidence intervals) at
baseline and follow up by treatment group (77 women in the isoflavone
group and 85 in the placebo; P = 0.82).
Table 2
Circulating levels of oestradiol, follicle-stimulating hormone and luteinizing hormone at baseline and after 12 months, and change
from baseline to 12 months by treatment group
Isoflavone group (n = 56) Placebo (n = 61)a
Baseline 12 months Change Baseline 12 months Change P for changeb
Oestradiol (pmol/l)  22.6 ± 12.2 36.6 ± 65.0 14.0 ± 64.7 22.6 ± 13.3 21.6 ± 9.0 –0.9 ± 11.5 0.49
FSH (IU/l) 76.2 ± 21.5 72.0 ± 23.5 –4.2 ± 12.9 77.6 ± 25.1 74.5 ± 23.9 –2.9 ± 13.0 0.83
LH (IU/l) 43.9 ± 15.4 39.9 ± 14.6 –4.0 ± 11.7 45.5 ± 16.0 41.2 ± 12.0 –4.2 ± 9.2 0.71
Values are expressed as means ± standard deviation. aFor change in FSH, n = 60. bP value for difference between treatment groups for change.
FSH, follicle-stimulating hormone; LH, luteinizing hormone.Reported effects of soy intakes on gonadotrophins have
also been inconsistent, with limited data showing either no
effect [49,51,55] or decreases in FSH and LH with soy
supplementation [53]. Despite the fact that this was one
of the longest and largest studies to have investigated the
effects of an isoflavone supplement on the hormonal
status of postmenopausal women, we did not observe a
significant effect of the isoflavone supplement on
circulating levels of oestradiol, FSH or LH.
Phyto-oestrogens have been postulated to have several
other anticancer effects and, because of the possible role
of genistein as an inhibitor of protein tyrosine kinase
activity [56], we investigated levels of lymphocyte tyrosine
kinase activity. However, we were unable to show
significant differences between treatment groups for the
change in the levels of lymphocyte tyrosine kinase activity.
Soy and phyto-oestrogens have received considerable
attention because of their potential role in relieving
menopausal symptoms, but their efficacy in such a role
remains to be fully established. Short-term intervention
studies among women experiencing frequent hot flushes
have shown reductions in the frequency and/or severity of
hot flushes with soy consumption, but also among control
individuals [57–59], whereas others have shown little or
no effect [60–63]. However, in a recent study of women
experiencing more than five hot flushes per day, all study
participants were given a placebo tablet in a single-blind,
4-week run-in phase, and during the subsequent 12-week
double-blind phase the frequency of hot flushes was
reduced by 44% in the women taking two Promensil
tablets per day; no further reduction occurred in the
placebo group [64]. In our study, the occurrence of hot
flushes and the severity of menopausal symptoms
decreased to a similar extent in both treatment groups,
suggesting natural improvement over time. It is possible
that the lack of a significant treatment effect may, in part,
have been due to our study population; women were not
selected for the study on the basis of suffering from
severe or frequent hot flushes and/or other menopausal
symptoms. As a result, baseline levels of menopausal
symptoms were relatively low, which presumably limited
the room for improvement in the study.
Polymorphisms in genes involved in sex hormone
metabolism and in genes that encode hormone receptors
may have an effect on the production of and exposure to
sex hormones, and on the subsequent activation of genes
that are responsive to sex hormones. We investigated
interactions between treatment and selected poly-
morphisms in the CYP17 and CYP19 genes, both of which
are involved in the sex hormone biosynthesis pathway, and
the oestrogen receptor (ESR1) gene. Polymorphisms in
these genes have been associated with risk for breast
cancer in some but not all studies [65,66]. We saw
interesting potential gene–treatment effects for the
changes in breast density and ESR1 polymorphism and
FSH and CYP19 polymorphism, but the study was not
powered to investigate these interactions and a larger
study is needed to confirm these findings.
Using the PABA check method as an independent marker
of compliance, and urinary excretion of isoflavones,
compliance with study procedures appeared to be
excellent. However, a potential limitation of this study is
that, although the study size was based on a case–control
study of tamoxifen and breast density [19], changes in
breast density among control individuals in this study were
greater than anticipated. In addition, our findings may not
be generalizable to the population as a whole. We did not
include women in this study who were taking HRT at the
time of recruitment (approximately one-third of women in
the UK between the ages of 50 and 64 years use HRT
[67]), and we only selected women with Wolfe P2 or DY
breast patterns (which comprised approximately 60% of
all mammograms classified for recruitment purposes). A
further limitation of the study is that several statistical tests
were carried out, and some of the statistically significant
findings may have been due to chance.
Conclusion
We found that a dietary supplement that provided 26 mg
biochanin A, 16 mg formononetin, 1 mg genistein and
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Table 3
Daily number of hot flushes and menopausal symptom score at baseline and after 12 months, and change from baseline to 12
months by treatment group
Isoflavone (n = 45, n = 70)a Placebo (n = 54, n = 83)a
Baseline 12 months Change Baseline 12 months Change P for changeb
Mean daily number of hot flushes 2.1 ± 2.7 1.2 ± 2.3 –0.8 ± 2.1 2.5 ± 3.0 1.5 ± 2.0 –1.0 ± 1.8 0.41
Menopausal symptom score 4.3 ± 4.3 3.4 ± 4.1 –0.9 ± 4.1 4.3 ± 4.3 3.5 ± 3.8 –0.8 ± 2.8 0.88
Analyses based on women who reported hot flushes or menopausal symptoms in one or both diaries. Values are expressed as means ± standard
deviation. aShown in parentheses are the number of women with hot flushes and number of women with any menopausal symptoms, respectively.
bP value for difference between treatment groups for change.0.5 mg daidzein daily for 1 year did not increase mammo-
graphic breast density in women aged 49–65 years, unlike
conventional oestrogen replacement therapies. Further-
more, there were no effects of the isoflavone supplement
on oestradiol, FSH or LH in postmenopausal women, or
on hot flushes or other menopausal symptoms. Taken
together, our findings suggest that the isoflavone supple-
ment at the dose given was not acting as an oestrogen or
as an anti-oestrogen.
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